Skip to main content
Clinical Trials/NL-OMON50723
NL-OMON50723
Completed
Not Applicable

Effects of almond consumption on chronic glucose regulation, vascular function and cognitive performance: The AL-INCLUSIVE trial - Almonds and Health

niversiteit Maastricht0 sites84 target enrollmentStarted: TBDLast updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
84

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • \- Aged between 40\-75 years
  • \- Men and women
  • \- BMI between 25\-40 kg/m2 (overweight and obese)
  • \- Being classified as having prediabetes, either having impaired glucose
  • tolerance (IGT) and/or having impaired fasting glucose (IFG). IGT is defined
  • according the criteria of the WHO and American Diabetes Association (ADA) as
  • two\-hour glucose concentrations of 7\.8 to 11\.0 mmol/l (140 to 199 mg per dL)
  • during the 75\-g oral glucose tolerance test. IFG is defined as having a fasting
  • plasma glucose between 6\.1 and 7\.0 mmol/l (110 to 125 mg per dL) and a two\-hour
  • glucose concentration below 7\.8 mmol/l (140 mg per dL).

Exclusion Criteria

  • \- Allergy or intolerance to almonds
  • \- Serum total cholesterol \* 8\.0 mmol/L
  • \- Serum triacylglycerol \* 4\.52 mmol/L
  • \- Current smoker, or smoking cessation \<12 months
  • \- Diabetic patients
  • \- Familial hypercholesterolemia
  • \- Abuse of drugs
  • \- More than 4 alcoholic consumptions per day or 21 per week
  • \- Unstable body weight (weight gain or loss \> 3 kg in the past three months)
  • \- Use medication known to treat blood pressure, lipid or glucose metabolism

Investigators

Similar Trials